Valeant Pharma (VRX) Issues Comments on Anonymous Press Reports

Valeant (VRX) 3Q Earnings Preview: Underlying RX Trends Remain Weak - Wells Fargo

Wells Fargo analyst David Maris issued a Q3 preview of Valeant Pharmaceuticals (NYSE: VRX), saying while the company should have some tailwinds for 3Q including price increases, cost cuts, and a now fixed Walgreens deal; however, Valeant's underlying U.S. prescription trends remain... More

Valeant Pharma (VRX) Trades at New Lows Amid Ex-Executive Probe

Valeant Pharma (NYSE: VRX) is trading at fresh 52-week lows following reports ex-CEO, Michael Pearson and ex.-CFO, Howard Schiller, are the focus of criminal probe related potential accounting fraud tied to the company's hidden Philidor Rx Services company.

Shares last traded down 12.4% to $17.83.

Valeant ex-CEO, ex-CFO focus of U.S. criminal probe: Bloomberg

(Reuters) - U.S. prosecutors are focusing on Valeant Pharmaceuticals International Inc's (NYSE: VRX) former chief executive and chief financial officer as they build a fraud case against the drugmaker, Bloomberg reported.

The case against Valeant could yield charges within weeks, the report said, citing people familiar with the matter. (http://bloom.bg/2fnXLYp)

U.S. authorities are looking into potential accounting fraud charges related... More

Valeant Pharma (VRX) option volume and volatility increases on sharp sell off

Valeant Pharma (NYSE: VRX) November weekly put option implied volatility is at 130, November is at 133; compared to its 52-week range of 53 to 176.

Valeant Pharma (VRX) ex-CEO, ex.-CFO Said to Be Focus of Criminal Probe

(Updated - October 31, 2016 3:32 PM EDT)

Valeant Pharma (NYSE: VRX) ex-CEO, Michael Pearson and ex.-CFO, Howard Schiller, are said to be focus of criminal probe, according to Bloomberg.

UPDATE - Authorities are looking into potential accounting fraud tied to the company's hidden... More